Termeer: "It can't go on forever"

Genzyme's CEO spent a good part of Monday burnishing the prospects of their experimental MS drug alemtuzumab, and thereby the value of the big biotech. With Sanofi so far unwilling to budge from its $69 offer, and Genzyme just as insistent on refusing to entertain such a price, Henri Termeer was limited to making fresh enthusiastic noises about a possible contingent value rights deal. But for now there's nothing new on prospective talks with Sanofi. "Clearly," said Termeer, "we will have conversations at the right moment...It can't go on forever."Story

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.